瑞舒伐他汀在改变急性冠脉综合征合并心律失常患者炎性因子水平中的应用分析.docVIP

精品论文 参考文献 瑞舒伐他汀在改变急性冠脉综合征合并心律失常患者炎性因子水平中的应用分析 汪永辉 李程 　　（泸县人民医院 四川 泸县 646100） 　　【摘要】 目的：对瑞舒伐他汀在改变急性冠脉综合征合并心律失常患者炎性因子水平中的应用效果进行评价分析。方法：选择我院急性冠脉综合并心律失常患者128例进行分组研究，另选择同期健康体检者130例作为健康对照组进行临床研究。结果：瑞舒伐他汀组、常规治疗组患者治疗前血清hs-CRP、TNF-alpha;、IL-18水平均较健康对照组发生显著升高，治疗2周后，各组患者的血清hs-CRP、TNF-alpha;、IL-18水平较治疗前均发生明显降低，且瑞舒伐他汀组患者的血清hs-CRP、TNF-alpha;、IL-18水平低于常规治疗组。结论：瑞舒伐他汀可有效改善急性冠脉综合征患者血清因子水平。 　　【关键词】 瑞舒伐他汀；急性冠脉综合征；心律失常；炎性因子；治疗 　　【中图分类号】R541.7 【文献标识码】A 【文章编号】2095-1752（2016）13-0054-02 　　【Abstract】Objective To rosuvastatin was evaluated in patients with acute coronary change analysis merger inflammatory cytokine levels in patients with cardiac arrhythmias application effect syndrome. Methods Rosuvastatin group, the conventional treatment group patients before treatment serum hs-CRP, TNF-alpha;, IL-18 levels than those in the healthy control group had significantly increased, two weeks after treatment, serum hs-CRP in each group of patients, TNF -alpha;, IL-18 levels than before treatment were significantly lower occurrence and rosuvastatin serum hs-CRP statin group of patients, TNF-alpha;, IL-18 levels lower than the conventional therapy group. Results: rosuvastatin group, the conventional treatment group patients before treatment serum hs-CRP, TNF-alpha;, IL-18 levels than those in the healthy control group had significantly higher treatment two weeks, each group of patients with serum hs-CRP , TNF-alpha;, IL-18 levels than before treatment were significantly lower occurrence and rosuvastatin group is greater than the reduction in the conventional therapy group. Conclusion Rosuvastatin can effectively improve the serum factor in patients with acute coronary syndrome. 　　【Key words】the acute coronary syndrome; acute coronary syndrome; arrhythmia; inflammatory factors; treatment. 　　本次研究对我院收治的符合诊断标准[1]的急性冠脉综合征合并心律失常住院患者治疗前后的炎性因子水平进行了检测，并对检测结果与健康对照组进行了对比分析，结果汇报如下。 　　1.资料与方法 　　1.1 一般资料 　　研究中资料来源于我院收治的符合临床诊断标准的急性冠脉综合征合并心律失常住院患者及其同期健康体检者，分别选择其中的128例和130例